United States· US:82804-261_e3fbea8c-bc0d-4dcd-a14e-a4575dceeea6

Oxaprozin

A oxaprozin product containing oxaprozin, registered in United States by Proficient Rx LP. The same ATC class is registered in 4 of our 19 countries.

ATC M01AE12US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedOxaprozinATCM01AE12REGISTER NO.US:82804-261_e3fbea8c…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Oxaprozin is registered in 4 of 19 countries.

Countries holding a registration under ATC M01AE12 (oxaprozin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose

Oxaprozin · ATC M01AE12

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Japan
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
OXAPROZIN
Manufacturer
Proficient Rx LP
Country
United States (US)
ATC code
M01AE12
ATC class
Oxaprozin
Defined daily dose
0.9 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    8280426160
    60 TABLET, FILM COATED in 1 BOTTLE (82804-261-60)
  • ndc11
    82804-261-60

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

245 interactions on record for oxaprozin.

Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Oxaprozin · interactions on record

245 records

  • 57 severe
  • 140 moderate
  • 5 minor
  • 43 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Oxaprozin in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All oxaprozin products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Greece · Nisaid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d82ea549-29b0-406f-8754-7bb9ba8c0d84
GET /v1/drugs/d82ea549-29b0-406f-8754-7bb9ba8c0d84?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "600",
  "substance": "OXAPROZIN",
  "productndc": "82804-261",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA075855",
  "marketing_category": "ANDA"
}

See everything about oxaprozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.